These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 7581092

  • 21. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
    Elias AD, Ayash L, Tepler I, Wheeler C, Schwartz G, Mazanet R, Schnipper L, Frei E, Antman K.
    J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
    [Abstract] [Full Text] [Related]

  • 22. Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvests.
    Zimmerman TM, Lee WJ, Bender JG, Mick R, Williams SF.
    Bone Marrow Transplant; 1995 Mar; 15(3):439-44. PubMed ID: 7541269
    [Abstract] [Full Text] [Related]

  • 23. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
    Hohaus S, Goldschmidt H, Ehrhardt R, Haas R.
    Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
    [Abstract] [Full Text] [Related]

  • 24. Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).
    Meisenberg BR, Miller WE, McMillan R.
    Bone Marrow Transplant; 1996 Dec; 18(6):1087-93. PubMed ID: 8971377
    [Abstract] [Full Text] [Related]

  • 25. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW, Long GD, Stockerl-Goldstein KE, Johnston LJ, Chao NJ, Negrin RS, Blume KG.
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [Abstract] [Full Text] [Related]

  • 26. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
    Mohr M, Hilgenfeld E, Fietz T, Hoppe B, Koenigsmann M, Hoffmann M, Knauf WU, Cassens U, Sibrowski W, Kienast J, Thiel E, Berdel WE.
    Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
    [Abstract] [Full Text] [Related]

  • 28. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH, Fay JP, Christiansen NP, Pinero L, Shah D, Stephan M, Herzig GP.
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [Abstract] [Full Text] [Related]

  • 29. Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.
    Grigg A, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath KM, Morstyn G, Fox RM, Sheridan WP.
    Bone Marrow Transplant; 1993 Sep; 11 Suppl 2():23-9. PubMed ID: 8334435
    [Abstract] [Full Text] [Related]

  • 30. [Favorable effect of hematopoietic stem cells isolated from blood on hematologic recovery following high-dosage chemotherapy].
    Richel DJ, Baars JW, Wijngaarden MJ, van der Schoot CE, Vlasveld LT, Rodenhuis S.
    Ned Tijdschr Geneeskd; 1993 Jan 30; 137(5):245-50. PubMed ID: 7679478
    [Abstract] [Full Text] [Related]

  • 31. High dose therapy and autologous bone marrow versus blood cell rescue. South Island Bone Marrow Transplant Unit.
    Hill GR, Inder A, Patton WN, Hart DN.
    N Z Med J; 1996 Feb 23; 109(1016):45-8. PubMed ID: 8598936
    [Abstract] [Full Text] [Related]

  • 32. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W.
    Bone Marrow Transplant; 1996 Feb 23; 17(2):149-55. PubMed ID: 8640159
    [Abstract] [Full Text] [Related]

  • 33. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
    Watanabe H, Watanabe T, Suzuya H, Wakata Y, Kaneko M, Onishi T, Okamoto Y, Abe T, Kawano Y, Kagami S, Takaue Y.
    Bone Marrow Transplant; 2006 Apr 23; 37(7):661-8. PubMed ID: 16489358
    [Abstract] [Full Text] [Related]

  • 34. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.
    Sautois B, Fraipont V, Baudoux E, Fassotte MF, Hermanne JP, Jérusalem G, Bours V, Bosquée L, Schaaf-Lafontaine N, Paulus JM, Sondag D, Fillet G, Beguin Y.
    Haematologica; 1999 Apr 23; 84(4):342-9. PubMed ID: 10190949
    [Abstract] [Full Text] [Related]

  • 35. Progenitor content of autologous grafts: mobilized bone marrow vs mobilized blood.
    Dahl E, Burroughs J, DeFor T, Verfaillie C, Weisdorf D.
    Bone Marrow Transplant; 2003 Sep 23; 32(6):575-80. PubMed ID: 12953129
    [Abstract] [Full Text] [Related]

  • 36. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation.
    Kiss JE, Rybka WB, Winkelstein A, deMagalhaes-Silverman M, Lister J, D'Andrea P, Ball ED.
    Bone Marrow Transplant; 1997 Feb 23; 19(4):303-10. PubMed ID: 9051238
    [Abstract] [Full Text] [Related]

  • 37. A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
    Smith RJ, Sweetenham JW.
    Exp Hematol; 1995 Dec 23; 23(14):1581-8. PubMed ID: 8542950
    [Abstract] [Full Text] [Related]

  • 38. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
    Cesana C, Carlo-Stella C, Regazzi E, Garau D, Sammarelli G, Caramatti C, Tabilio A, Mangoni L, Rizzoli V.
    Bone Marrow Transplant; 1998 Mar 23; 21(6):561-8. PubMed ID: 9543059
    [Abstract] [Full Text] [Related]

  • 39. Hematological recovery and peripheral blood progenitor cell mobilization after induction chemotherapy and GM-CSF plus G-CSF in breast cancer.
    Charrier S, Chollet P, Bay JO, Curé H, Kwiatkowski F, Portefaix G, Communal Y, Bétail G, Plagne R, Chassagne J.
    Bone Marrow Transplant; 2000 Apr 23; 25(7):705-10. PubMed ID: 10745254
    [Abstract] [Full Text] [Related]

  • 40. Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer.
    Tomás JF, Pérez-Carrión R, Escudero A, López-Lorenzo JL, López-Pascual J, Fernández-Rañada JM.
    Bone Marrow Transplant; 1997 Feb 23; 19(4):331-6. PubMed ID: 9051242
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.